News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
574,496 Results
Type
Article (41148)
Company Profile (161)
Press Release (533187)
Multimedia
Podcasts (44)
Webinars (12)
Section
Business (160676)
Career Advice (2461)
Deals (28975)
Drug Delivery (102)
Drug Development (75071)
Employer Resources (142)
FDA (13767)
Job Trends (12791)
News (283750)
Policy (27631)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (6)
2024 Genetown Digital (6)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Genetown Standard (1)
2026 Pharm Country Standard (1)
Academia (2577)
Academic (1)
Accelerated approval (5)
Adcomms (26)
Allergies (78)
Alliances (41088)
ALS (91)
Alzheimer's disease (1404)
Antibody-drug conjugate (ADC) (132)
Approvals (13761)
Artificial intelligence (243)
Autoimmune disease (24)
Automation (16)
Bankruptcy (314)
Best Places to Work (10398)
BIOSECURE Act (18)
Biosimilars (90)
Biotechnology (136)
Bladder cancer (68)
Brain cancer (25)
Breast cancer (260)
Cancer (2097)
Cardiovascular disease (180)
Career advice (2072)
Career pathing (33)
CAR-T (146)
Cell therapy (407)
Cervical cancer (16)
Clinical research (61059)
Collaboration (764)
Compensation (321)
Complete response letters (22)
COVID-19 (2512)
CRISPR (41)
C-suite (246)
Cystic fibrosis (87)
Data (2051)
Decentralized trials (2)
Denatured (6)
Depression (49)
Diabetes (255)
Diagnostics (5797)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (38)
Drug discovery (117)
Drug pricing (93)
Drug shortages (23)
Duchenne muscular dystrophy (89)
Earnings (57617)
Editorial (37)
Employer branding (18)
Employer resources (129)
Events (83685)
Executive appointments (710)
FDA (14892)
Featured Employer (28)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (687)
Gene editing (99)
Generative AI (19)
Gene therapy (298)
GLP-1 (697)
Government (4168)
Grass and pollen (5)
Guidances (50)
Healthcare (16327)
Huntington's disease (24)
IgA nephropathy (26)
Immunology and inflammation (127)
Indications (26)
Infectious disease (2657)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (90)
Interviews (522)
IPO (13175)
IRA (42)
Job creations (2805)
Job search strategy (1700)
Kidney cancer (11)
Labor market (22)
Layoffs (423)
Leadership (21)
Legal (5926)
Liver cancer (74)
Lung cancer (311)
Lymphoma (140)
Machine learning (6)
Management (51)
Manufacturing (268)
MASH (72)
Medical device (10655)
Medtech (10659)
Mergers & acquisitions (16291)
Metabolic disorders (659)
Multiple sclerosis (76)
NASH (23)
Neurodegenerative disease (96)
Neuropsychiatric disorders (31)
Neuroscience (1936)
NextGen: Class of 2025 (5695)
Non-profit (4024)
Northern California (2284)
Now hiring (31)
Obesity (341)
Opinion (217)
Ovarian cancer (72)
Pain (86)
Pancreatic cancer (79)
Parkinson's disease (147)
Partnered (18)
Patents (219)
Patient recruitment (103)
Peanut (44)
People (53167)
Pharmaceutical (29)
Pharmacy benefit managers (10)
Phase I (19027)
Phase II (26904)
Phase III (20254)
Pipeline (1113)
Policy (133)
Postmarket research (2334)
Preclinical (7849)
Press Release (65)
Prostate cancer (92)
Psychedelics (37)
Radiopharmaceuticals (223)
Rare diseases (366)
Real estate (4616)
Recruiting (57)
Regulatory (19511)
Reports (25)
Research institute (2186)
Resumes & cover letters (359)
Rett syndrome (4)
RNA editing (2)
RSV (39)
Schizophrenia (72)
Series A (121)
Series B (79)
Service/supplier (6)
Sickle cell disease (55)
Southern California (2031)
Special edition (10)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3022)
State (2)
Stomach cancer (14)
Supply chain (61)
Tariffs (27)
The Weekly (37)
United States (19784)
Vaccines (640)
Venture capitalists (33)
Weight loss (231)
Women's health (27)
Worklife (18)
Date
Last 7 days (599)
Last 30 days (2160)
Last 365 days (29825)
2025 (9002)
2024 (32051)
2023 (35749)
2022 (46409)
2021 (49887)
2020 (48046)
2019 (41004)
2018 (31079)
2017 (28225)
2016 (27012)
2015 (31460)
2014 (23955)
2013 (19526)
2012 (20906)
2011 (21902)
2010 (19580)
Location
Africa (751)
Alabama (49)
Alaska (4)
Arizona (151)
Arkansas (11)
Asia (35500)
Australia (7218)
California (5249)
Canada (1826)
China (473)
Colorado (222)
Connecticut (231)
Delaware (125)
Europe (79081)
Florida (797)
Georgia (170)
Idaho (51)
Illinois (482)
India (24)
Indiana (275)
Iowa (7)
Japan (151)
Kansas (92)
Kentucky (18)
Louisiana (8)
Maine (49)
Maryland (793)
Massachusetts (3805)
Michigan (194)
Minnesota (327)
Mississippi (1)
Missouri (75)
Montana (25)
Nebraska (22)
Nevada (53)
New Hampshire (63)
New Jersey (1506)
New Mexico (21)
New York (1511)
North Carolina (846)
North Dakota (6)
Northern California (2284)
Ohio (167)
Oklahoma (8)
Oregon (26)
Pennsylvania (1145)
Puerto Rico (11)
Rhode Island (28)
South America (1043)
South Carolina (18)
South Dakota (1)
Southern California (2031)
Tennessee (86)
Texas (796)
Utah (168)
Virginia (130)
Washington D.C. (53)
Washington State (518)
West Virginia (3)
Wisconsin (42)
574,496 Results for "chrysalis biotherapeutics formerly known as chrysalis biotechnology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lone Star Bio
Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit
Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.
May 6, 2024
·
2 min read
Press Releases
Chrysalis BioTherapeutics, Inc. Announces Collaboration with NIAID to Evaluate Chrysalin® for the Treatment of Cutaneous Radiation Injury
November 18, 2024
·
2 min read
Drug Development
Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)
Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure.
September 26, 2023
·
2 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 1, 2025
·
3 min read
Press Releases
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
April 8, 2025
·
7 min read
Press Releases
Radiant Biotherapeutics Announces Poster Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
April 25, 2025
·
1 min read
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
April 23, 2025
·
8 min read
1 of 57,450
Next
